Skip to main content

Advertisement

Log in

The clinical potential of sphingolipid-based therapeutics

  • Visions & Reflections
  • Published:
Cellular and Molecular Life Sciences CMLS Aims and scope Submit manuscript

Abstract.

The era of sphingolipid-based therapeutics is upon us. A large body of work has been accumulating that demonstrates the distinct biological roles of sphingolipids in maintaining a homeostatic environment and in responding to environmental stimuli to regulate cellular processes. It is thus necessary to further investigate alterations in sphingolipid-metabolism in pathological conditions and, in turn, try to exploit altered sphingolipid-me- tabolizing enzymes and their metabolites as therapeutic targets. This review will examine how advances in the fields of drug delivery, drug discovery, synthetic chemistry, enzyme replacement therapy, immunobiology, infectious disease and nanotechnology have delivered the potential and promise of utilizing and/or targeting sphingolipid metabolites as therapies for diverse diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R. Blumenthal.

Additional information

Received 11 November 2005; received after revision 19 January 2006; accepted 30 January 2006

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, T.E., Finnegan, C.M., Blumenthal, R. et al. The clinical potential of sphingolipid-based therapeutics. Cell. Mol. Life Sci. 63, 1017–1023 (2006). https://doi.org/10.1007/s00018-005-5543-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00018-005-5543-z

Keywords.

Navigation